Evaluation of a Pulsed-Xenon Ultraviolet Room Disinfection Device

脉冲氙紫外线房间消毒装置的评估

基本信息

  • 批准号:
    8487186
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-05-01 至 2016-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Pulsed Xenon Technology Targeting Hospital Acquired Infections, Cost and Outcomes Background and Introduction: Hospital acquired infections (HAI), frequently transmitted via contaminated environmental surfaces, affect 1.7 million patient infections and result in 100,000 deaths annually, along with substantial extra treatment costs. Recognizing increasing challenges of treating multiple drug resistant pathogens (e.g., MRSA, C.difficile), VA initiatives have targeted HAI reductions, such as screenings, active surveillance, and patient isolation. While transmission rates have declined, most preventive strategies to reduce infection are only partially effective, and proper disinfection is rarely achieved. Leveraging promising pilot data and close collaboration among VA facilities, this implementation study will determine the clinical and economic benefits of a powerful new decontamination technology, since hand cleaning of discharged patient rooms requires substantial time, labor and supply costs. The anticipated reduction in infection rates and future ramifications such as unnecessary readmissions, plus efficient use of VA resources, offer numerous strong advantages over current cleaning procedures. Future applications include use in other VA inpatient settings and contract nursing homes where HAI presents a significant problem for aging veterans. The Central Texas Veterans Health Care System alone experiences 8000 annual admissions/transfers, each necessitating an intensive cleaning. Unfortunately, manual efforts focusing on visible soiled areas are usually insufficient and unreliable (70% of high-touch surfaces are missed). However, portable machines emitting pulsed xenon ultraviolet rays (PX-UV) waves represent an effective, convenient solution for providing safer patient environments without disrupting hospital operations. PX-UV effectively kills many microbial pathogens with shorter cleaning times, yielding a practical, less expensive option for routine room disinfection. Our recent pilot study compared human-only efforts to PX-UV cleaning: MRSA and bacterial colony counts dropped precipitously and cost analyses were suggested lower expenditures for PX-UV devices. Yet wider implementation is needed to validate this work, and demonstrate global implications for routine quality improvement efforts. Proposed Methods: Our experienced multidisciplinary team will link facility infection control reports, observations of labor resources compared with new technology costs, and VA administrative data, this larger evaluation study will demonstrate the clinical impact, implementation feasibility, and cost- effectiveness of the innovative disinfection system. If PX-UV is clinically and economically superior to standard cleaning protocol while reducing adverse outcomes, we believe study findings can potentially revolutionize hospital procedures. At two intervention facilities, rooms and surgical suites will be disinfected with PX-UV, while two control sites will continue practicing standard manual cleaning. Infection control reports will be collected, documenting new HAI cases and microbial counts at selected high-touch room surfaces for multiple organisms. This information will be linked to patient-level administrative data extracts for diagnostic information, treatment costs, and health utilization variables. Addressing our primary objectives: 1) The clinical impact of this new technology will be assessed by differential reductions in microbial counts between intervention and control sites. 2) As a result, HAI transmission rates will significantly decrease; 3) Finally, a rigorous cost-effectiveness analysis will examine economic cost savings including labor time and fewer hospital days and use of antibiotics to treat HAI.
描述(由申请人提供): 背景和介绍:医院获得性感染(HAI)经常通过污染的环境表面传播,每年影响170万患者感染并导致10万人死亡,沿着大量额外的治疗费用。认识到治疗多种耐药病原体(例如,MRSA、艰难梭菌),VA计划的目标是减少HAI,如筛查、主动监测和患者隔离。虽然传播率有所下降,但大多数减少感染的预防性战略仅部分有效,而且很少实现适当的消毒。利用有前途的试点数据和VA设施之间的密切合作,这项实施研究将确定一个强大的新的去污技术的临床和经济效益,因为出院患者房间的手部清洁需要大量的时间,劳动力和供应成本。感染率的预期降低和未来的后果,如不必要的再入院,加上VA资源的有效利用,提供了许多强大的优势,目前的清洁程序。未来的应用包括在其他VA住院设置和合同疗养院,其中HAI提出了一个显着的问题,为老年退伍军人使用。仅得克萨斯州中部退伍军人医疗保健系统每年就有8000人入院/转院,每一次都需要进行密集的清洁。不幸的是,人工专注于可见的污染区域通常是不够的和不可靠的(70%的高接触表面被错过)。然而,发射脉冲氙紫外线(PX-UV)波的便携式机器代表了一种有效、方便的解决方案,用于提供更安全的患者环境,而不会中断医院运营。PX-UV可有效杀灭多种微生物病原体,且清洁时间更短,为常规房间消毒提供了一种实用且成本更低的选择。我们最近的试点研究比较了人类的努力,PX-UV清洁:MRSA和细菌菌落计数急剧下降,成本分析表明,PX-UV设备的支出较低。然而,需要更广泛的实施,以验证这项工作,并证明日常质量改进工作的全球影响。建议的方法:我们经验丰富的多学科团队将联系设施感染控制报告、与新技术成本相比的劳动力资源观察结果以及VA管理数据,这项更大的评估研究将证明创新消毒的临床影响、实施可行性和成本效益。 系统如果PX-UV在临床和经济上上级标准清洁方案,同时减少不良后果,我们相信研究结果可能会彻底改变医院程序。在两个干预机构,房间和手术室将使用PX-UV消毒,而两个对照部位将继续进行标准手动清洁。将收集感染控制报告,记录新的HAI病例和选定高接触房间表面的多种微生物计数。这些信息将链接到诊断信息、治疗费用和健康利用变量的患者级管理数据提取。实现我们的主要目标:1)这项新技术的临床影响将通过干预和对照部位之间微生物计数的差异减少来评估。2)因此,HAI传播率将显著降低; 3)最后,严格的成本效益分析将检查经济成本节约,包括劳动时间和更少的住院天数以及使用抗生素治疗HAI。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John E Zeber其他文献

John E Zeber的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了